With the COVID-19 pandemic accelerating digital adoption, most of the organisations in the pharmaceutical industry are confident about digital transformation growth.
GlobalData has conducted a survey to assess the optimism in the industry about the prospects of digital transformation in the next 12 months.
Outlook of Digital Transformation Growth in the Next 12 Months
An analysis of the survey results shows that more than 70% of the respondents were optimistic about the growth of digital transformation in their organisations.
While 19% of the surveyed respondents were very optimistic, 54% had an optimistic outlook.
Furthermore, 22% were neither optimistic nor pessimistic, while 4% were pessimistic. Very pessimistic were just 1% of the total respondents.
The survey also found that the optimism about digital transformation was consistent across all business sizes and geographies.
Among large companies with revenues of more than $1bn, 24% were very optimistic and 55% were optimistic, while 18% were neutral and 3% very pessimistic.
Among medium-sized enterprises (revenues from $100m to $1bn), 16% were very optimistic and 57% were optimistic, while 23% were neutral and 5% were pessimistic.
Among small companies (revenues less than $100m), the percentage of respondents who were very optimistic was 13% and optimistic was 55%, while 26% were neutral and 6% were pessimistic.
Region-wise, 21% in North America were very optimistic and 59% were optimistic about digital transformation in their organisations. The percentages were 20% and 48% in Europe, and 9% and 45% in Asia Pacific, respectively.
The analysis is based on Digital Transformation and Emerging Technology in the Healthcare Industry, 2020 survey, fielded from 17 September to 06 October 2020.
